I agree that this site is using cookies. You can find further informations here.
X
van Weelderen, Romy E.
31  results:
Search for persons X
?
1

Optimized cytogenetic risk-group stratification of KMT2A-re..:

van Weelderen, Romy E. ; Harrison, Christine J. ; Klein, Kim...
Blood Advances.  8 (2024)  12 - p. 3200-3213 , 2024
Link: https://doi.org/10.1182/..
 
?
2

Treatment outcomes of pediatric acute myeloid leukemia in W..:

van Weelderen, Romy E. ; Wijnen, Noa E. ; Njuguna, Festus...
Cancer Reports.  6 (2023)  8 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
3

Effect of Antibacterial Prophylaxis on Febrile Neutropenic ..:

Van Weelderen, Romy E. ; Klein, Kim ; Goemans, Bianca F....
Cancers.  14 (2022)  13 - p. 3172 , 2022
Link: https://doi.org/10.3390/..
 
?
4

Outcomes of pediatric acute myeloid leukemia treatment in W..:

van Weelderen, Romy E. ; Njuguna, Festus ; Klein, Kim...
Cancer Reports.  5 (2021)  10 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

Outcome of pediatric acute myeloid leukemia (AML) in low- a..:

Van Weelderen, Romy E ; Klein, Kim ; Natawidjaja, Meyrina D..
Expert Review of Anticancer Therapy.  21 (2021)  7 - p. 765-780 , 2021
Link: https://doi.org/10.1080/..
 
?
6

Optimized cytogenetic risk-group stratification of KMT2A-re..:

van Weelderen, Romy E ; Harrison, Christine J ; Klein, Kim...
https://pure.eur.nl/en/publications/50ac940e-30e3-4570-a22c-520de592de85.  , 2024
Link: https://pure.eur.nl/en/p..
 
?
7

Optimized cytogenetic risk-group stratification of KMT2A-re..:

van Weelderen, Romy E ; Harrison, Christine J ; Klein, Kim...
https://pure.au.dk/portal/en/publications/41b94d65-8984-40bd-9cd9-cfe51cd9b4a7.  , 2024
Link: https://pure.au.dk/porta..
 
?
8

Treatment outcomes of pediatric acute myeloid leukemia in W..:

van Weelderen, Romy E ; Wijnen, Noa E ; Njuguna, Festus...
10.1002/cnr2.1849.  , 2023
Link: https://hdl.handle.net/1..
 
?
9

Treatment outcomes of pediatric acute myeloid leukemia in W..:

van Weelderen, Romy E ; Wijnen, Noa E ; Njuguna, Festus...
https://research.vumc.nl/en/publications/5c024c28-7d2d-4257-bc5b-de952e60986f.  , 2023
Link: https://research.vumc.nl..
 
?
10

Measurable Residual Disease and Fusion Partner Independentl..:

van Weelderen, Romy E ; Klein, Kim ; Harrison, Christine J...
https://research.vumc.nl/en/publications/837bc95f-e282-464a-beb3-9cb01df08e8c.  , 2023
Link: https://research.vumc.nl..
 
?
11

Measurable residual disease and fusion partner independentl..:

van Weelderen, Romy E ; Klein, Kim ; Harrison, Christine J...
Journal of Clinical Oncology, 0732-183X, 2023, 41:16, s. 2963-2974.  , 2023
Link: http://urn.kb.se/resolve..
 
?
12

Measurable Residual Disease and Fusion Partner Independentl..:

van Weelderen, Romy E ; Klein, Kim ; Harrison, Christine J...
info:eu-repo/semantics/altIdentifier/pmid/36996387.  , 2023
Link: https://hdl.handle.net/1..
 
?
13

Measurable Residual Disease and Fusion Partner Independentl..:

van Weelderen, Romy E ; Klein, Kim ; Harrison, Christine J...
https://research.vumc.nl/en/publications/837bc95f-e282-464a-beb3-9cb01df08e8c.  , 2023
Link: https://research.vumc.nl..
 
?
14

Measurable Residual Disease and Fusion Partner Independentl..:

van Weelderen, Romy E ; Klein, Kim ; Harrison, Christine J...
https://pure.eur.nl/en/publications/d91778f2-d863-42bc-a447-a84c2da899dd.  , 2023
Link: https://pure.eur.nl/en/p..
 
?
15

Measurable Residual Disease and Fusion Partner Independentl..:

van Weelderen, Romy E ; Klein, Kim ; Harrison, Christine J...
https://pure.eur.nl/en/publications/d91778f2-d863-42bc-a447-a84c2da899dd.  , 2023
Link: https://pure.eur.nl/en/p..
 
1-15